企業プロフィール
Incyte 株価・ニュース・カタリスト
- ティッカー:
- INCY
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Wilmington, Delaware
株価パフォーマンス
117.14 USD (-3.47%)
終値
最終更新: 2026年10月1日
18.4B USD
時価総額
株価変動の要因
2026年10月1日 時点で INCY は 3.47% 下落し、$117.14 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Research-Based Biopharmaceutical Company
Incyte discovers, develops, and commercializes medicines across hematology, oncology, and inflammation and autoimmunity. The company has built an internal discovery engine around targeted small molecules and biologics while expanding its commercial footprint through both wholly owned and partnered products.
Hematology Franchise
The hematology business is anchored by Jakafi and Jakafi XR across myelofibrosis, polycythemia vera, and graft-versus-host disease. Monjuvi/Minjuvi and Niktimvo extend the franchise into B-cell lymphoma and chronic graft-versus-host disease, while INCA033989 targets mutant calreticulin in myeloproliferative neoplasms.
Oncology Portfolio
Incyte's oncology portfolio includes Zynyz and Pemazyre as well as clinical candidates targeting KRAS G12D, TGF-beta receptor 2, and CDK2. Development emphasizes biomarker-defined tumors and combinations with established chemotherapy, antibodies, and antiangiogenic agents.
Dermatology and Autoimmune Medicines
Opzelura is a topical JAK inhibitor commercialized for atopic dermatitis and vitiligo, with studies underway in additional inflammatory skin diseases. Povorcitinib, an oral JAK1 inhibitor, is being developed across hidradenitis suppurativa, prurigo nodularis, asthma, and other immune-mediated conditions.
Acquired and Partnered Pipeline
The acquisition of Vega Therapeutics added latarcibart, a once-monthly antibody in Phase 3 development for von Willebrand disease. Incyte also uses collaborations for formulation technology, regional commercialization, and selected pipeline assets, complementing its internally generated programs.
今後のカタリスト
- Potential U.S. approval and launch of Monjuvi for newly diagnosed diffuse large B-cell lymphoma in the first quarter of 2027.
- Topline Phase 2 data for axatilimab plus ruxolitinib in newly diagnosed chronic graft-versus-host disease in the second half of 2026.
- Presentation of INCB161734 and INCA33890 Phase 1 combination data at ESMO 2026.
- Initiation of a Phase 3 study of INCB123667 in first-line maintenance ovarian cancer in the second half of 2026.
- Phase 3 TRuE-HS1 and TRuE-HS2 topline results for ruxolitinib cream in hidradenitis suppurativa in the fourth quarter of 2026.
- Potential European launch of povorcitinib in late 2026 and potential U.S. approval and launch in the first quarter of 2027.
- Phase 3 STOP-PN1 and STOP-PN2 data for povorcitinib in prurigo nodularis in the fourth quarter of 2026.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。